Citius Oncology, Inc. (CTOR) — Cash Flow-to-Debt Ratio
Citius Oncology, Inc. (CTOR) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-3.97 Million could theoretically repay 0% of its total liabilities ($65.43 Million) in one year. Check CTOR cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Citius Oncology, Inc. Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Citius Oncology, Inc. across 4 annual periods. Also explore Citius Oncology, Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Citius Oncology, Inc. (2022–2025)
Year-by-year debt coverage analysis for Citius Oncology, Inc.. For market capitalisation and broader financial context, see market value of Citius Oncology, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | $-5.49 Million | $56.08 Million | ▼ -3063.2% |
| 2024 | 0.00x | $126.35K | $38.23 Million | ▲ +112.2% |
| 2023 | -0.03x | $-601.30K | $22.20 Million | ▼ -262.7% |
| 2022 | -0.01x | $-47.97K | $6.42 Million | — |